Profile data is unavailable for this security.
About the company
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.
- Revenue in USD (TTM)6.34bn
- Net income in USD1.61bn
- Incorporated2012
- Employees10.60k
- LocationZoetis Inc10 Sylvan WayPARSIPPANY 07054-3825United StatesUSA
- Phone+1 (973) 822-7000
- Fax+1 (302) 655-5049
- Websitehttps://www.zoetis.com/
Mergers & acquisitions
| Acquired company | ZTS:NYQ since announced | Transaction value |
|---|---|---|
| Performance Livestock Analytics | 8.71% | -- |
| Ethos Diagnostic Science | -1.35% | -- |
| ZNLabs LLC | 14.04% | -- |
| Phoenix Central Laboratory For Veterinarians Inc | 7.45% | -- |
| Platinum Performance Inc | 20.17% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc | 7.98bn | 2.28bn | 63.57bn | 8.10k | 31.19 | 5.74 | 25.48 | 7.97 | 19.90 | 19.90 | 69.66 | 108.15 | 0.5578 | 0.8897 | 3.05 | 985,160.50 | 15.93 | 17.80 | 18.20 | 20.74 | 89.72 | 92.16 | 28.56 | 25.67 | 3.72 | 19.18 | 0.0557 | 0.00 | 17.18 | 22.77 | -10.97 | 44.30 | 5.23 | -- |
| Zoetis Inc | 6.34bn | 1.61bn | 65.11bn | 10.60k | 40.78 | 23.65 | 32.00 | 10.27 | 3.36 | 3.36 | 13.23 | 5.80 | 0.5657 | 1.35 | 6.55 | 598,018.90 | 14.38 | 11.62 | 16.43 | 13.71 | 69.70 | 66.83 | 25.41 | 18.90 | 1.91 | 10.30 | 0.7013 | 22.90 | 7.47 | 5.52 | 8.46 | 20.80 | 20.64 | 17.02 |
| Vertex Pharmaceuticals Incorporated | 4.82bn | 1.51bn | 76.34bn | 3.00k | 51.10 | 11.81 | 47.20 | 15.84 | 5.76 | 5.76 | 18.43 | 24.94 | 0.6244 | 3.80 | 7.51 | 1,606,498.00 | 19.58 | 5.48 | 23.62 | 6.99 | 87.24 | 87.50 | 31.35 | 9.03 | 3.42 | -- | 0.0762 | 0.00 | 36.59 | 48.30 | 119.39 | -- | 8.06 | -- |
| Gilead Sciences, Inc. | 22.72bn | 4.96bn | 95.73bn | 11.80k | 19.62 | 4.34 | 15.13 | 4.21 | 3.89 | 3.89 | 17.86 | 17.60 | 0.3706 | 4.98 | 6.32 | 1,925,085.00 | 8.05 | 18.07 | 9.48 | 21.88 | 79.37 | 83.42 | 21.72 | 39.31 | 2.92 | 21.20 | 0.5207 | 25.34 | 1.46 | -2.04 | -1.34 | -14.95 | 8.17 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2020 | 35.98m | 7.58% |
| BlackRock Fund Advisorsas of 31 Mar 2020 | 23.22m | 4.89% |
| SSgA Funds Management, Inc.as of 31 Mar 2020 | 20.07m | 4.23% |
| State Farm Investment Management Corp.as of 31 Mar 2020 | 18.13m | 3.82% |
| AllianceBernstein LPas of 31 Mar 2020 | 14.18m | 2.99% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2020 | 11.54m | 2.43% |
| Polen Capital Management LLCas of 31 Mar 2020 | 9.77m | 2.06% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2020 | 9.47m | 1.99% |
| ClearBridge Investments LLCas of 31 Mar 2020 | 9.09m | 1.91% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2020 | 8.25m | 1.74% |
